Literature DB >> 18305015

Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.

Kathryn O'Leary1, Neeraja Parameswaran, J Michael McIntosh, Maryka Quik.   

Abstract

The nicotine metabolite cotinine is an abundant long-lived bio-active compound that may contribute to the overall physiological effects of tobacco use. Although its mechanism of action in the central nervous system has not been extensively investigated, cotinine is known to evoke dopamine release in the nigrostriatal pathway through an interaction at nicotinic receptors (nAChRs). Because considerable evidence now demonstrates the presence of multiple nAChRs in the striatum, the present experiments were done to determine the subtypes through which cotinine exerts its effects in monkeys, a species that expresses similar densities of striatal alpha4beta2* (nAChR containing the alpha4 and beta2 subunits, but not alpha3 or alpha6) and alpha3/alpha6beta2* (nAChR composed of the alpha3 or alpha6 subunits and beta2) nAChRs. Competition binding studies showed that cotinine interacts with both alpha4beta2* and alpha3/alpha6beta2* nAChR subtypes in the caudate, with cotinine IC(50) values for inhibition of 5-[(125) I]iodo-3-[2(S)-azetinylmethoxy]pyridine-2HCl ([(125)I]A-85380) and (125)I-alpha-conotoxinMII binding in the micromolar range. This interaction at the receptor level is of functional significance because cotinine stimulated both alpha4beta2* and alpha3/alpha6beta2* nAChR [(3)H]dopamine release from caudate synaptosomes. Our results unexpectedly showed that nicotine evokes [(3)H]dopamine release from two alpha3/alpha6beta2* nAChR populations, one of which was sensitive to cotinine and the other was not. This cotinine-insensitive subtype was only present in the medial caudate and was preferentially lost with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal damage. In contrast, cotinine and nicotine elicited equivalent levels of alpha4beta2* nAChR-mediated dopamine release. These data demonstrate that cotinine functionally discriminates between two alpha3/alpha6beta2* nAChRs in monkey striatum, with the cotinine-insensitive alpha3/alpha6beta2* nAChR preferentially vulnerable to nigrostriatal damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305015      PMCID: PMC3134143          DOI: 10.1124/jpet.108.136838

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography.

Authors:  David C Perry; Yingxian Xiao; Henry N Nguyen; John L Musachio; Martha I Dávila-García; Kenneth J Kellar
Journal:  J Neurochem       Date:  2002-08       Impact factor: 5.372

3.  Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes.

Authors:  P J Vainio; R K Tuominen
Journal:  Nicotine Tob Res       Date:  2001-05       Impact factor: 4.244

4.  Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.

Authors:  M Quik; Y Polonskaya; J M Kulak; J M McIntosh
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

5.  Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.

Authors:  Jennifer M Kulak; John L Musachio; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

Review 6.  The potential role of cotinine in the cognitive and neuroprotective actions of nicotine.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Life Sci       Date:  2003-05-16       Impact factor: 5.037

7.  Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain.

Authors:  R D Schwartz; J Lehmann; K J Kellar
Journal:  J Neurochem       Date:  1984-05       Impact factor: 5.372

8.  Cotinine inhibits catecholamine release evoked by cholinergic stimulation from the rat adrenal medulla.

Authors:  Young-Yeop Koh; Seok-Jeong Jang; Dong-Yoon Lim
Journal:  Arch Pharm Res       Date:  2003-09       Impact factor: 4.946

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.

Authors:  Jennifer M Kulak; Jocelyn Sum; John L Musachio; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

View more
  25 in total

Review 1.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  The nicotine metabolite, cotinine, alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors.

Authors:  Ashley M Fox; Faruk H Moonschi; Christopher I Richards
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

3.  Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.

Authors:  Pei Li; Wayne D Beck; Patrick M Callahan; Alvin V Terry; Michael G Bartlett
Journal:  Pharmacol Rep       Date:  2014-12-16       Impact factor: 3.024

4.  Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.

Authors:  Tanuja Bordia; Carla Campos; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

5.  Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats.

Authors:  Julie A Marusich; Mahesh Darna; A George Wilson; Emily D Denehy; Amanda Ebben; Agripina G Deaciuc; Linda P Dwoskin; Michael T Bardo; Timothy W Lefever; Jenny L Wiley; Chad J Reissig; Kia J Jackson
Journal:  Eur J Pharmacol       Date:  2017-08-26       Impact factor: 4.432

6.  Smoke extracts and nicotine, but not tobacco extracts, potentiate firing and burst activity of ventral tegmental area dopaminergic neurons in mice.

Authors:  Fabio Marti; Ouafa Arib; Carole Morel; Virginie Dufresne; Uwe Maskos; Pierre-Jean Corringer; Renaud de Beaurepaire; Philippe Faure
Journal:  Neuropsychopharmacology       Date:  2011-06-29       Impact factor: 7.853

7.  Functional characterization of the α5(Asn398) variant associated with risk for nicotine dependence in the α3β4α5 nicotinic receptor.

Authors:  Ping Li; Megan McCollum; John Bracamontes; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2011-08-19       Impact factor: 4.436

8.  6-hydroxy-L-nicotine from Arthrobacter nicotinovorans sustain spatial memory formation by decreasing brain oxidative stress in rats.

Authors:  Lucian Hritcu; Marius Stefan; Roderich Brandsch; Marius Mihasan
Journal:  J Physiol Biochem       Date:  2012-06-20       Impact factor: 4.158

9.  A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2009-07-03       Impact factor: 5.858

Review 10.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.